Flow Cytometric Immune Profiling in Infliximab-Associated Tuberculosis

Kelly Pennington, Humberto C. Sasieta, Guiherme P. Ramos, Courtney L. Erskine, Virginia P. Van Keulen, Tobias Peikert, Patricio Escalante

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Tumor necrosis factor α antagonists are increasingly used to treat inflammatory and autoimmune disorders and are associated with increased risk of active tuberculosis. Diagnosis of active tuberculosis in patients taking tumor necrosis factor α antagonists can be challenging owing to increased incidence of extrapulmonary manifestations and false-negative results on current available diagnostic tests. We present a case of a young woman on infliximab for ulcerative colitis who presented with disseminated tuberculosis. As part of a research study, we performed flow cytometric immune profiling, which has previously not been reported in patients with active tuberculosis taking tumor necrosis α antagonists. The flow cytometry results were within the positive thresholds for tuberculosis infection. Flow cytometric immune profiling may be a valid diagnostic tool for patients taking tumor necrosis factor α antagonists.

Original languageEnglish (US)
Pages (from-to)1-3
Number of pages3
JournalClinical Medicine Insights: Case Reports
StatePublished - Aug 7 2017


  • Tumor necrosis factor alpha antagonists
  • active tuberculosis
  • flow cytometry
  • inflammatory bowel disease

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Flow Cytometric Immune Profiling in Infliximab-Associated Tuberculosis'. Together they form a unique fingerprint.

Cite this